SAGE Therapeutics, Inc.
(NASDAQ : SAGE)

( )
SAGE After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corporation Plc Sponsored ADR
-0.17%17.232.0%$168.99m
PRGOPerrigo Co. Plc
2.30%45.906.8%$129.89m
SAGESAGE Therapeutics, Inc.
2.44%139.799.5%$122.46m
JAZZJazz Pharmaceuticals Plc
1.32%129.072.2%$96.51m
GWPHGW Pharmaceuticals PLC Sponsored ADR
2.07%137.296.3%$79.66m
PTLAPortola Pharmaceuticals, Inc.
3.59%26.537.7%$62.96m
ICPTIntercept Pharmaceuticals, Inc.
-0.19%113.4518.6%$56.62m
MNKMallinckrodt Plc
3.72%20.6421.1%$46.44m
CTLTCatalent Inc
1.12%35.612.4%$43.31m
AXSMAxsome Therapeutics, Inc.
-1.92%8.162.7%$41.31m
UTHRUnited Therapeutics Corporation
1.37%115.7514.4%$40.84m
ICLRICON Plc
-0.18%133.184.1%$40.29m
ENDPEndo International Plc
-1.52%9.708.9%$37.43m
HZNPHorizon Pharma plc
-1.71%21.847.4%$29.17m
MDCOMedicines Company
0.25%20.0021.8%$28.86m

Company Profile

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.